CCT3 drives Sorafenib resistance by inhibiting TFRC-mediated iron uptake in HCC
CCT3 drives Sorafenib resistance by inhibiting TFRC-mediated iron uptake in HCC
About this item
Full title
Author / Creator
Publisher
Cold Spring Harbor: Cold Spring Harbor Laboratory Press
Journal title
Language
English
Formats
Publication information
Publisher
Cold Spring Harbor: Cold Spring Harbor Laboratory Press
Subjects
More information
Scope and Contents
Contents
Sorafenib is commonly utilized in the management of advanced hepatocellular carcinoma (HCC). However, its efficacy in extending patients' survival is hindered by the development of drug resistance. By employing protein posttranslational modification (PTM) omics, including acetylome, phosphoproteome, and ubiquitinome, in conjunction with genome-wide...
Alternative Titles
Full title
CCT3 drives Sorafenib resistance by inhibiting TFRC-mediated iron uptake in HCC
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_biorxiv_primary_2023_12_14_571783
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_biorxiv_primary_2023_12_14_571783
Other Identifiers
ISSN
2692-8205
E-ISSN
2692-8205
DOI
10.1101/2023.12.14.571783
